Placebo News and Research

RSS
Idera reports $6.0 million net loss for fourth quarter 2010

Idera reports $6.0 million net loss for fourth quarter 2010

10 Mar 2011
Positive results from Creabilis CT327 Phase IIa study in patients with psoriasis vulgaris

Positive results from Creabilis CT327 Phase IIa study in patients with psoriasis vulgaris

10 Mar 2011
Santarus commences SAN-300 Phase I clinical study to treat inflammatory diseases

Santarus commences SAN-300 Phase I clinical study to treat inflammatory diseases

10 Mar 2011
FDA approves BENLYSTA for active, autoantibody-positive systemic lupus erythematosus

FDA approves BENLYSTA for active, autoantibody-positive systemic lupus erythematosus

10 Mar 2011
Auxilium completes patient enrollment in XIAFLEX phase III trial against Peyronie's disease

Auxilium completes patient enrollment in XIAFLEX phase III trial against Peyronie's disease

9 Mar 2011
Human Genome Sciences receives FDA approval for Benlysta to treat lupus

Human Genome Sciences receives FDA approval for Benlysta to treat lupus

9 Mar 2011
Unique gene therapy to combat Parkinson's disease

Unique gene therapy to combat Parkinson's disease

9 Mar 2011
Novartis QAB149 receives FDA Pulmonary-Allergy Advisory Committee approval for COPD

Novartis QAB149 receives FDA Pulmonary-Allergy Advisory Committee approval for COPD

9 Mar 2011
Treatment with sildenafil significantly reduces RP in patients with scleroderma

Treatment with sildenafil significantly reduces RP in patients with scleroderma

8 Mar 2011
Recent rituximab trial with TNF inhibitors reports no new safety risks in patients with RA

Recent rituximab trial with TNF inhibitors reports no new safety risks in patients with RA

8 Mar 2011
Fumaric acid salts may protect against Multiple Sclerosis

Fumaric acid salts may protect against Multiple Sclerosis

8 Mar 2011
Top-line results from Repligen RG2417 Phase 2b trial results in patients with bipolar depression

Top-line results from Repligen RG2417 Phase 2b trial results in patients with bipolar depression

8 Mar 2011
5a-reductase inhibitors for male health problems can affect sexual health

5a-reductase inhibitors for male health problems can affect sexual health

7 Mar 2011
Solasia, ZIOPHARM enter license and collaboration agreement for darinaparsin product

Solasia, ZIOPHARM enter license and collaboration agreement for darinaparsin product

7 Mar 2011
Inovio initiates VGX-3100 Phase II trial in patients with cervical cancer

Inovio initiates VGX-3100 Phase II trial in patients with cervical cancer

7 Mar 2011
iPrEx update, bone mineral density study highlighted at day three of 18th CROI

iPrEx update, bone mineral density study highlighted at day three of 18th CROI

5 Mar 2011
FDA approves change to prescribing information for Gilead Sciences' Letairis

FDA approves change to prescribing information for Gilead Sciences' Letairis

5 Mar 2011
Researchers use qMRI to confirm effect of CS treatment in patients with OA

Researchers use qMRI to confirm effect of CS treatment in patients with OA

5 Mar 2011
Monthly liver enzyme tests not required for PAH patients taking Letairis tablets: FDA

Monthly liver enzyme tests not required for PAH patients taking Letairis tablets: FDA

5 Mar 2011
Combination therapy may reduce albuminuria in patients with type 2 diabetes: Study

Combination therapy may reduce albuminuria in patients with type 2 diabetes: Study

5 Mar 2011

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback